Privately held Seamless Therapeutics announced a global research and licensing agreement worth up to $1.12B with Eli Lilly to develop gene-editing treatments for hearing loss.
#LLYStock #EliLilly#GeneEditing #SeamlessTherapeutics #Biotech
0
0
0
0